Earlier this week, the Harvard Law School opened a psychedelics policy center, which it believes will be useful to physicians navigating this growing field as more policies of reform are approved. The Project on Psychedelics Law and Regulation, as the center will be known, has been established to promote equity, innovation and safety in psychedelics therapeutics, commerce and research.
A press release by the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard acknowledges that local and state psychedelics development involves assessments of the effects of policy as well as the possible impact of private companies that seek to enter this burgeoning market.
The project’s director Mason Marks, who also happens to be a senior fellow at the Petrie-Flom Center, stated that only a few psychedelic research centers exist at different learning institutions in the country that center on clinical research, noting that there wasn’t any systematic research being done on psychedelics law. He also asserted that the Project on Psychedelics Law and Regulation, which has been dubbed POPLAR, would help fill the gap.
Marks, who is also a member of the state of Oregon’s psilocybin advisory board, has stated in an interview that the project would also work to address ethical issues that impact physicians who are working with psychedelic substances. He also talked about how federal legislations hindered the research on these substances.
There has been growing academic interest in psychedelic substances as more activists call for an end to the criminalization of substances such as ibogaine, DMT and psilocybin.
Earlier in 2019, the Johns Hopkins University opened the first center in the country that would focus on the research of psychedelic drugs, exclusively. Similarly, POPLAR will also look into psychedelics medical benefits, while also focusing on ethics and law.
Jeannie Suk, a law professor at Harvard, stated that prior research proposed that psychedelics held great benefits for individuals who suffered from PTSD and trauma, noting that by conducting an analysis of political, legal and social barriers to access with regard to the substances, the project could further the understanding of the substances’ possible effect as therapies.
POPLAR is being privately financed by individuals such as Matt Mullenweg, who played a huge role in the development of WordPress and is also the CEO of Automattic, and Tim Ferriss, a philanthropist who will be making his contributions through the Saisei Foundation. Both individuals also financed the Johns Hopkins psychedelic center.
The launch of the center focusing on psychedelics policy at Harvard University is a good complement to the work being done by companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) geared at developing psychedelic medicines targeting a number of diseases.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.